Table 1.
Univariate and multivariate Cox proportional hazards regression analyses demonstrating the independence of ClockLoss or ClockGain from other clinicopathological features
| Hazard ratio (95% CI) | P-value | |
|---|---|---|
| All gliomas (ClockLost) | Univariate | |
| Q2 vs. Q1 | 0.393 (0.285–0.543) | < 0.0001 |
| Q3 vs. Q1 | 0.274 (0.193–0.387) | < 0.0001 |
| Q4 vs. Q1 | 0.188 (0.127–0.278) | < 0.0001 |
| All gliomas (ClockGain) | Univariate | |
| Q2 vs. Q1 | 1.272 (0.813–1.991) | 0.29 |
| Q3 vs. Q1 | 2.931 (1.951–4.402) | < 0.0001 |
| Q4 vs. Q1 | 3.961 (2.668–5.882) | < 0.0001 |
| Astrocytoma (ClockGain) | Univariate | |
| Q2 vs. Q1 | 0.59 (0.242–1.468) | 0.26 |
| Q3 vs. Q1 | 1.423 (0.65–3.109) | 0.38 |
| Q4 vs. Q1 | 3.048 (1.514–6.137) | 0.0018 |
| Oligodendroglioma (ClockGain) | Univariate | |
| Q2 vs. Q1 | 0.947 (0.362–2.474) | 0.91 |
| Q3 vs. Q1 | 1.184 (0.475–2.951) | 0.72 |
| Q4 vs. Q1 | 2.764 (1.194–6.400) | 0.018 |
| Pan-kidney (ClockLost) | Univariate | |
| Q2 vs. Q1 | 0.783 (0.547–1.121) | 0.18 |
| Q3 vs. Q1 | 0.801 (0.568–1.131) | 0.21 |
| Q4 vs. Q1 | 0.520 (0.352–0.768) | 0.001 |
| TNM staging | 2.095 (1.858–2.361) | < 0.0001 |
| Multivariate | ||
| Q2 vs. Q1 | 0.783 (0.543–1.129) | 0.18 |
| Q3 vs. Q1 | 0.764 (0.537–1.089) | 0.14 |
| Q4 vs. Q1 | 0.569 (0.383–0.847) | 0.0055 |
| TNM staging | 2.085 (1.848–2.354) | < 0.0001 |
| Pan-kidney (ClockGain) | Univariate | |
| Q2 vs. Q1 | 1.237 (0.838–1.825) | 0.28 |
| Q3 vs. Q1 | 1.222 (0.828–1.803) | 0.31 |
| Q4 vs. Q1 | 1.890 (1.311–2.725) | 0.00066 |
| Multivariate | ||
| Q2 vs. Q1 | 1.177 (0.790–1.752) | 0.42 |
| Q3 vs. Q1 | 1.429 (0.961–2.124) | 0.078 |
| Q4 vs. Q1 | 1.941 (1.333–2.826) | 0.00054 |
| TNM staging | 2.092 (1.857–2.357) | < 0.0001 |
| Clear cell renal cell (ClockLost) | Univariate | |
| Q2 vs. Q1 | 0.608 (0.416–0.888) | 0.01 |
| Q3 vs. Q1 | 0.546 (0.361–0.795) | 0.0019 |
| Q4 vs. Q1 | 0.292 (0.179–0.474) | < 0.0001 |
| TNM staging | 1.87 (1.641–2.132) | < 0.0001 |
| Multivariate | ||
| Q2 vs. Q1 | 0.653 (0.447–0.955) | 0.027 |
| Q3 vs. Q1 | 0.667 (0.448–0.993) | 0.046 |
| Q4 vs. Q1 | 0.433 (0.265–0.708) | 0.00085 |
| TNM staging | 1.798 (1.572–2.058) | < 0.0001 |
| Clear cell renal cell (ClockGain) | Univariate | |
| Q2 vs. Q1 | 1.243 (0.799–1.933) | 0.33 |
| Q3 vs. Q1 | 1.001 (0.640–1.564) | 0.99 |
| Q4 vs. Q1 | 1.775 (1.177–2.678) | 0.0062 |
| Multivariate | ||
| Q2 vs. Q1 | 1.222 (0.786–1.901) | 0.37 |
| Q3 vs. Q1 | 1.284 (0.818–2.017) | 0.28 |
| Q4 vs. Q1 | 1.856 (1.230–2.802) | 0.0032 |
| TNM staging | 1.874 (1.642–2.138) | < 0.0001 |
| Bladder (ClockLost) | Univariate | |
| Q2 vs. Q1 | 1.088 (0.593–1.999) | 0.78 |
| Q3 vs. Q1 | 1.478 (0.828–2.640) | 0.19 |
| Q4 vs. Q1 | 2.081 (1.198–3.614) | 0.0093 |
| TNM staging | 1.679 (1.323–2.131) | < 0.0001 |
| Multivariate | ||
| Q2 vs. Q1 | 1.059 (0.577–1.946) | 0.85 |
| Q3 vs. Q1 | 1.357 (0.759–2.426) | 0.31 |
| Q4 vs. Q1 | 1.776 (1.018–3.099) | 0.043 |
| TNM staging | 1.609 (1.263–2.050) | 1.20E−04 |
| Stomach (ClockLost) | Univariate | |
| Q2 vs. Q1 | 0.761 (0.389–1.485) | 0.43 |
| Q3 vs. Q1 | 1.143 (0.615–2.127) | 0.67 |
| Q4 vs. Q1 | 2.155 (1.255–3.702) | 0.0054 |
| TNM staging | 1.372 (1.067–1.765) | 0.038 |
| Multivariate | ||
| Q2 vs. Q1 | 0.731 (0.374–1.428) | 0.36 |
| Q3 vs. Q1 | 1.133 (0.609–2.107) | 0.69 |
| Q4 vs. Q1 | 2.070 (1.205–3.557) | 0.0084 |
| TNM staging | 1.354 (1.054–1.739) | 0.018 |
| Lung (ClockGain) | Univariate | |
| Q2 vs. Q1 | 1.633 (0.987–2.699) | 0.056 |
| Q3 vs. Q1 | 1.604 (0.973–2.644) | 0.064 |
| Q4 vs. Q1 | 2.023 (1.224–3.343) | 0.006 |
| TNM staging | 1.597 (1.364–1.870) | < 0.0001 |
| Multivariate | ||
| Q2 vs. Q1 | 1.604 (0.971–2.652) | 0.065 |
| Q3 vs. Q1 | 1.434 (0.868–2.370) | 0.16 |
| Q4 vs. Q1 | 1.832 (1.108–3.029) | 0.018 |
| TNM staging | 1.584 (1.348–1.861) | < 0.0001 |
| Pancreas (ClockGain) | Univariate | |
| Q2 vs. Q1 | 1.791 (0.849–3.779) | 0.13 |
| Q3 vs. Q1 | 1.602 (0.740–3.470) | 0.23 |
| Q4 vs. Q1 | 3.034 (1.492–6.168) | 0.0022 |
| TNM staging | 1.339 (0.897–1.998) | 0.153 |
| Multivariate | ||
| Q2 vs. Q1 | 1.712 (0.803–3.652) | 0.16 |
| Q3 vs. Q1 | 1.584 (0.731–3.430) | 0.24 |
| Q4 vs. Q1 | 2.890 (1.399–5.970) | 0.0042 |
| TNM staging | 1.143 (0.756–1.728) | 0.52 |